Sustainability | January 23, 2025
Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
This transformation will enable GE HealthCare to build a strong foundation for business growth
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Integration of modern and traditional medicine to facilitate the illness to wellness journey
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Subscribe To Our Newsletter & Stay Updated
